Table 4.
Description of treatment outcomes by STK pathway (clinical trial cohort).
| mTOR/AKT/PI3K pathway |
Aurora pathway |
MAPK/MEK/Raf pathway |
||||||
|---|---|---|---|---|---|---|---|---|
| All STK inhibitors | All pathways | mTOR | AKT | PI3K | All pathways | All pathways | Sorafenib | |
| Response rates (RECIST) | ||||||||
| No. of subjects (n) | 442a | 108 | 63 | 25 | 20 | 82 | 272 | 185 |
| Response rate (%) | 13 | 13 | 8 | 4 | 40 | 6 | 17 | 17 |
| Clinical benefit rateb (%) | 67 | 56 | 44 | 28 | 95 | 69 | 71 | 68 |
| Complete response (%) | 1 | 1 | 0 | 0 | 5 | 0 | 2 | 2 |
| Partial responseb (%) | 12 | 12 | 8 | 4 | 35 | 6 | 15 | 15 |
| Stable disease (%) | 52 | 39 | 44 | 24 | 55 | 61 | 53 | 51 |
| Progressive diseaseb (%) | 32 | 44 | 56 | 72 | 5 | 29 | 28 | 30 |
| Response rates (CA125) | ||||||||
| No. of subjects (n) | 175 | 21 | 0 | 21 | 0 | 51 | 103 | 56 |
| Response rates (%) | 21 | 10 | 0 | 10 | 0 | 20 | 23 | 32 |
| Survival time (months)c | ||||||||
| PFS | 3.4 | 3.2 | 3.2 | 1.9 | 7.0 | 2.0 | 4.6 | 3.7 |
| OS | 13.0 | 8.0 | 11.6 | 4.5 | n/a | 9.8 | 15.2 | 15.2 |
Response rate includes complete response and partial response. Clinical benefit rate includes complete response, partial response, and stable disease.
Not all subjects included in Table 2 were evaluable for treatment response so numbers differ.
Two trials (87 subjects) did not include data on rates of stable disease and progressive disease, so these subjects were removed from analysis of clinical benefit rate, stable disease, and progressive disease (for study with mTOR pathway inhibitor with temsirolims, subgroup of the study showed at least 53% of clinical benefit rate based on 51 cases reporting treatment response).
Survival time described from study enrollment to final status, numbers are described as median of median reported in each study (not available for all studies).
STK: Serine–threonine kinases; mTOR: mammalian target of rapamycin; AKT: protein kinase B; PI3K: phosphatidylinositol 3-kinase; MAPK: mitogen-activated protein kinase; MEK: mitogen-activated protein kinase kinase; PFS: progression-free survival; OS: overall survival; SD: stable disease; PD: progressive disease.